Drugs / PM1022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05867771 | Apr 2022 → Apr 2024 | metastatic neoplasm | BioNTech SE | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM1022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05867771 ↗ |
| Route | Intravenous | “PM1022 administered as a single-agent by IV infusion every 3 weeks” NCT05867771 ↗ |
| Target | TIGIT | “PM1022 is a recombinant humanized anti-PDL1 and anti-TIGIT bispecific antibody.” NCT05867771 ↗ |